JAK
Los inhibidores de la Janus quinasa (JAK) son compuestos que se dirigen a la vía de señalización JAK-STAT, la cual está involucrada en el crecimiento celular, la respuesta inmunitaria y la angiogénesis. Al inhibir JAK, estos compuestos pueden reducir la señalización que conduce a la formación de nuevos vasos sanguíneos en los tumores, inhibiendo así el crecimiento tumoral. Los inhibidores de JAK son importantes en el tratamiento del cáncer y las enfermedades inflamatorias. En CymitQuimica, ofrecemos una amplia gama de inhibidores de JAK de alta calidad para apoyar su investigación en oncología, inmunología y angiogénesis.
Se han encontrado 245 productos de "JAK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tyrphostin AG 490
CAS:Fórmula:C17H14N2O3Pureza:>98.0%(T)(HPLC)Forma y color:White to Light yellow powder to crystalPeso molecular:294.31N-(3-Aminopropyl)cyclohexylamine
CAS:<p>N-(3-Aminopropyl)cyclohexylamine inhibits spermine synthase; used in neuro disease research.</p>Fórmula:C9H20N2Pureza:98.05% - 98.82%Forma y color:Pale Yellow Clear LiquidPeso molecular:156.2685Golidocitinib
CAS:<p>Golidocitinib (AZD4205) is a selective JAK1 inhibitor (IC50: 73 nM) and weakly inhibits JAK2/JAK3 (IC50: >14.7, >30 μM).</p>Fórmula:C25H31N9O2Pureza:98.87% - 99.88%Forma y color:SolidPeso molecular:489.57Ilginatinib hydrochloride
CAS:<p>Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.</p>Fórmula:C21H21ClFN7Pureza:99.55%Forma y color:SolidPeso molecular:425.89Ilginatinib maleate
CAS:<p>Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable inhibitor of JAK2.</p>Fórmula:C25H24FN7O4Pureza:99.74% - 99.82%Forma y color:SolidPeso molecular:505.5Brepocitinib P-Tosylate
CAS:<p>Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).</p>Fórmula:C25H29F2N7O4SPureza:99.82% - 99.97%Forma y color:SolidPeso molecular:561.6TAK-901
CAS:<p>TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others</p>Fórmula:C28H32N4O3SPureza:99.02% - 99.59%Forma y color:SolidPeso molecular:504.64Delgocitinib
CAS:<p>Delgocitinib is a potent JAK inhibitor (IC50: 2.8-58 nM), treats inflammatory diseases, and is the first topical drug for atopic dermatitis.</p>Fórmula:C16H18N6OPureza:99.95%Forma y color:SolidPeso molecular:310.35Gusacitinib
CAS:<p>Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).</p>Fórmula:C24H28N8O2Pureza:98.06% - 99.94%Forma y color:SolidPeso molecular:460.53Ilginatinib
CAS:<p>Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.</p>Fórmula:C21H20FN7Pureza:98.4% - 99.01%Forma y color:SolidPeso molecular:389.43WDR5-IN-6
CAS:<p>WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6</p>Fórmula:C13H8Cl2N2O2SPureza:99.69%Forma y color:SoildPeso molecular:327.19Nimucitinib
CAS:<p>Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.</p>Fórmula:C25H26F2N6O2Pureza:98.71%Forma y color:SoildPeso molecular:480.51JAK2 Inhibitor V
CAS:<p>JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.</p>Fórmula:C23H24N2OPureza:98.36% - 99.15%Forma y color:SolidPeso molecular:344.45(E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide
CAS:Fórmula:C17H14N2O3Pureza:98%Forma y color:SolidPeso molecular:294.3047Povorcitinib phosphate
CAS:<p>Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.</p>Fórmula:C23H25F5N7O5PPureza:99.57%Forma y color:SolidPeso molecular:605.45JAK/HDAC-IN-4
<p>JAK/HDAC-IN-4 (compound 11 i) is a dual inhibitor targeting both JAK2 and HDAC6, with IC50 values of 0.49 nM and 12 nM respectively. It inhibits cell proliferation and the production of nitric oxide. In a mouse model induced by Imiquimod, JAK/HDAC-IN-4 ameliorates psoriasiform skin lesions with low toxicity.</p>Fórmula:C30H32N8O5SForma y color:SolidPeso molecular:616.69JAK-IN-29
<p>JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].</p>Fórmula:C17H14ClN5O2Pureza:98%Forma y color:SolidPeso molecular:355.78MR44397
<p>MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.</p>Fórmula:C23H26N4O2SForma y color:SolidPeso molecular:422.54TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Fórmula:C23H21FN4O2Forma y color:SolidPeso molecular:404.16485SJ988497
CAS:<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Fórmula:C36H36N10O5Forma y color:SolidPeso molecular:688.74DBL-6-13
<p>DBL-6-13 is an inhibitor of WDR5, displaying moderate binding affinity with dissociation constants (Kd) of 6.8 μM and 9.1 μM as determined by microscale thermophoresis analysis and fluorescence polarization analysis, respectively.</p>Fórmula:C25H38N4O3Forma y color:SolidPeso molecular:442.59JAK-IN-15
CAS:<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Fórmula:C22H23FN4O3SForma y color:SolidPeso molecular:442.51SJ1008030 formic
<p>SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with an</p>Fórmula:C43H45N13O9SPureza:98%Forma y color:SolidPeso molecular:919.96Deuruxolitinib
CAS:<p>Deuruxolitinib functions as an inhibitor of JAK1/2.</p>Fórmula:C17H18N6Forma y color:SolidPeso molecular:314.41Axltide
CAS:<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Fórmula:C63H107N19O20S2Pureza:98%Forma y color:SolidPeso molecular:1514.77TYD-68
<p>TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.</p>Forma y color:Odour SolidJAK2-IN-10
CAS:<p>JAK2-IN-10 (compound 5) is a potent inhibitor of JAK2v617f, with an IC50 value of ≤10 nM.</p>Fórmula:C33H33D3FN9O2Forma y color:SolidPeso molecular:612.71Tyk2-IN-22
CAS:<p>Tyk2-IN-22 (Compound A8) is a selective inhibitor of tyrosine kinase 2 (Tyk2), effectively inhibiting Tyk2, JAK1, and JAK3 with IC50 values of 9.7 nM, 148.6 nM, and 883.3 nM, respectively. Additionally, Tyk2-IN-22 suppresses downstream STAT5 phosphorylation.</p>Fórmula:C16H16ClN5O2Forma y color:SolidPeso molecular:345.78JAK2-IN-6
CAS:<p>JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.</p>Fórmula:C14H10ClN3OS2Pureza:99.64%Forma y color:SolidPeso molecular:335.83JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Fórmula:C30H33FN4O3SForma y color:SolidPeso molecular:548.67JI069
CAS:<p>JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.</p>Fórmula:C15H12Cl2N2O4SPureza:98.01%Forma y color:SolidPeso molecular:387.24HAT-SIL-TG-1&AT
<p>HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.</p>Fórmula:C60H69N17O11SForma y color:SolidPeso molecular:1236.36Pumecitinib
CAS:<p>Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.</p>Fórmula:C17H20N8O2SPureza:99.94%Forma y color:SoildPeso molecular:400.46JAK-STAT Compound Library
<p>A unique collection of 252 JAK/STAT signaling targeted compounds for high throughput and high content screening;</p>Forma y color:Odour SolidPROTAC TYK2 degradation agent1
CAS:<p>PROTAC TYK2 Agent1 selectively degrades TYK2, with a 14 nM DC50, for autoimmune research.</p>Fórmula:C55H69N13O7SPureza:98%Forma y color:SolidPeso molecular:1056.28AS2553627
CAS:<p>AS2553627 is a JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts.</p>Fórmula:C18H19N5OForma y color:SolidPeso molecular:321.38LH168
<p>LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.</p>Fórmula:C29H31F3N6O2SForma y color:SolidPeso molecular:584.66Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
CAS:<p>Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide derived from mouse JAK2, specifically composed of amino acids 475 to 491.</p>Fórmula:C88H138N20O34P2Pureza:98%Forma y color:SolidPeso molecular:2082.1SJ10542
CAS:<p>SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.</p>Fórmula:C41H46N12O5SForma y color:SolidPeso molecular:818.95JAK-2/3-IN-1
CAS:<p>JAK-2/3-IN-1 inhibits JAK-2/3 isoforms with sub-250 nM Ki; from US patent US8163732B2.</p>Fórmula:C20H12ClN3OForma y color:SolidPeso molecular:345.79JAK3-IN-15
<p>JAK3-IN-15 (compound 22) is a JAK3 inhibitor that reduces the secretion of p-JAK3 induced by LPS. It is utilized in research for rheumatoid arthritis.</p>Forma y color:Odour SolidTyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Forma y color:Odour SolidJAK1/TYK2-IN-1
CAS:<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Fórmula:C18H20F3N7OForma y color:SolidPeso molecular:407.401SJ1008030
CAS:<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Fórmula:C42H43N13O7SForma y color:SolidPeso molecular:873.94Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Forma y color:Odour SolidFDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Forma y color:LiquidWDR5 ligand 2
CAS:<p>WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.</p>Fórmula:C29H31F3N4O4Forma y color:SolidPeso molecular:556.576S-Ruxolitinib
CAS:<p>S-Ruxolitinib can be used in related research in the field of life sciences. Its product number is T3066 and CAS number is 1160597-27-2.</p>Fórmula:C17H18N6Pureza:98%Forma y color:SolidPeso molecular:306.37JAK-IN-33
<p>JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].</p>Pureza:98%Forma y color:Odour Solid
